Intellia Therapeutics, Inc. (NTLA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly results for Intellia Therapeutics, Inc. for the period ended March 31, 2026. Intellia is a clinical-stage biopharmaceutical company focused on developing CRISPR-based gene editing therapies. Key developments in the period include the reporting of positive topline data from the Phase 3 HAELO trial for lonvoguran ziclumeran (lonvo-z) in April 2026 and the lifting of FDA clinical holds on the Phase 3 trials for nexiguran ziclumeran (nex-z) in March 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $15.0 million | $16.6 million |
| Net Loss | $(96.2) million | $(114.3) million |
| Net Loss Per Share (Basic & Diluted) | $(0.81) | $(1.10) |
| Operating Expenses | $115.6 million | $137.4 million |
| Cash, Cash Equivalents & Marketable Securities | $517.2 million | $602.1 million (approx. based on prior period) |
| Net Cash Used in Operating Activities | $(117.3) million | $(148.9) million |
Material Changes vs. Prior Period
- Revenue: Collaboration revenue decreased by $1.6 million (9.5%) primarily due to reduced revenue from the AvenCell agreement and the absence of a specific milestone payment recognized in Q1 2025 under the Regeneron agreement.
- Operating Expenses: Total operating expenses decreased by $21.9 million.
- Research & Development (R&D): Decreased by $27.7 million, driven by lower external development costs for nex-z and lonvo-z, reduced employee-related expenses (following a workforce reduction in Jan 2025), and lower stock-based compensation.
- General & Administrative (G&A): Increased by $5.8 million, primarily due to higher legal expenses and consulting costs related to commercial infrastructure buildout.
- Liquidity: Cash and cash equivalents decreased from $155.5 million to $134.7 million. Marketable securities decreased from $449.7 million to $382.6 million. The company generated $33.6 million in net proceeds from at-the-market (ATM) offerings during the quarter.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- Lonvo-z (HAE): Positive Phase 3 topline data reported in April 2026 showed an 87% reduction in attacks. A rolling Biologics License Application (BLA) was initiated, with a planned U.S. launch in H1 2027.
- Nex-z (ATTR): FDA lifted clinical holds on MAGNITUDE and MAGNITUDE-2 trials in Q1 2026 following a review of a patient death (determined to be due to septic shock unrelated to the drug). Enrollment is resuming.
- Capital Resources: Management expects current cash, marketable securities, and collaboration funding to support operations into 2028. In April 2026 (subsequent event), the company completed a public offering raising approximately $194.6 million in net proceeds.
- Risks & Contingencies:
- Litigation: Ongoing patent infringement lawsuit with BlueAllele Corp. and a securities class action lawsuit (Gonzalez v. Intellia) regarding prior disclosures. The company states it cannot estimate potential losses at this stage.
- Regulatory: Risks associated with the novel nature of in vivo gene editing and potential delays in regulatory approval or commercialization.
Investor Verification Checklist
- Verify the timeline for the BLA submission and FDA review for lonvo-z following the positive Phase 3 data.
- Monitor the resumption and enrollment rates of the nex-z Phase 3 trials (MAGNITUDE and MAGNITUDE-2) post-clinical hold lift.
- Review the status of the BlueAllele patent litigation and the Gonzalez securities class action for potential financial impact.
- Assess the burn rate relative to the $517.2 million cash position and the impact of the subsequent $194.6 million equity raise on dilution.
- Confirm the commercial infrastructure buildout costs and the timeline for the H1 2027 launch of lonvo-z.